Dendritic cells (DCs) are the most professional antigen-presenting cells and play a central role in eliciting specific adaptive and humoral immune responses. These features make DCs a very attractive tool
for immunotherapeutic approaches by stimulating patients to develop their own immunity to cancer
System enables the efficient clinical-scale enrichment of CD14+
cells (monocytes), CD1c (BDCA-1)+
cells (myeloid DCs), or CD304 (BDCA-4)+
cells (plasmacytoid DCs) from whole blood. In combination with the MACS® GMP Product Line
Miltenyi Biotec offers a comprehensive portfolio optimized for the ex vivo
GMP-compliant generation of DC vaccines.